Blackstone secures $1.6B so far for new life sciences fund targeted at $5B+
The world's biggest alternative asset manager is further cementing itself in the life sciences industry with another fund dedicated to drug development. Blackstone confirmed on its earnings call on...
View ArticleFDA approves Axsome's acute migraine treatment after 2022 rejection
More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for the drug on Thursday to treat acute migraines with or without aura. The drug,...
View ArticleRegeneron wins appeals court orders backing halt on Eylea biosimilars
Two biotech companies failed to reverse orders barring them from selling biosimilars of Regeneron’s eye disease drug Eylea in rulings from a federal appeals court. The US Court of Appeals for the...
View ArticleVertex's non-opioid pain drug Journavx is approved by FDA
The FDA approved Vertex’s non-opioid drug for moderate-to-severe acute pain, bringing to market the first in a new class of alternatives to painkillers. The drug, known as suzetrigine, will have the...
View ArticleMaze and Metsera biotech IPOs to begin trading Friday
Obesity drug developer Metsera and kidney disease biotech Maze Therapeutics priced their Nasdaq IPOs on Thursday evening. Metsera {$MTSR} will raise $275 million and Maze {$MAZE} will raise $140...
View ArticleNovartis claims best earnings in years, validating shift to pure-play strategy
Novartis said Friday that last year was one of its "strongest" financial performances in its history following a multiyear reorg as a pure-play pharma company, bolstered by steady ...
View ArticleRoche separates CFO, informatics posts; Lilly execs land at Kailera, Neurocrine
→ Wafaa Mamilli’s first day as chief digital technology officer for Roche will be Feb. 10, according to a release on the eve of the Swiss pharma’s
View ArticleAbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 sales
The loss of Humira exclusivity was long expected to be a blow to AbbVie’s immunology dominance, but the Skyrizi-Rinvoq tandem keeps outpacing expectations. In its fourth-quarter and full-year 2024...
View ArticleCelltrion looks to buy US facilities to sidestep potential Trump tariffs
South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President Donald Trump’s potential tariffs on foreign-made pharmaceuticals. Trump is...
View ArticleDaiichi Sankyo taps new CEO, aims to build up ADC franchise
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer. Before starting that role in 2023 ...
View ArticleAstraZeneca scraps plan to expand UK vaccine site
AstraZeneca has canceled its plans to expand its vaccine manufacturing site in Speke, UK, after the new UK government trimmed funding for the project, a company spokesperson confirmed to Endpoints...
View ArticleEngland agrees to pay for Vertex’s sickle cell disease gene therapy
Vertex Pharmaceuticals and the National Health Service in England have reached a payment deal making the gene-edited therapy Casgevy available to certain people with sickle cell disease. The NHS said...
View ArticleGenentech joins suits against STD clinics over 340B discounts
Genentech is the latest drugmaker to sue the federal government over STD clinics it says are wrongfully receiving discounts through the federal 340B program. The company claimed Friday that several...
View ArticleAbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up...
The reports of AbbVie’s demise have been greatly exaggerated. Gone are the worries of Humira competition and its monumental patent cliff. The “lack of a shiny object” in the pipeline is a ...
View ArticleRFK Jr. continues to evade questions on vaccines and autism
Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines contribute to the development of autism. And in written responses to ...
View ArticleRFK Jr. hearings leave key GOP senator “struggling”; Drugmakers report Q4...
Welcome back to Endpoints Weekly, thanks for starting your weekend with us. This week’s news was dominated by Robert F. Kennedy Jr.’s confirmation hearings to be HHS Secretary, as Kennedy faced two...
View ArticleSionna seeks $135M IPO to fuel tests of cystic fibrosis drug candidates
Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last week. Sionna, which snagged some of its programs from AbbVie last year, hopes...
View ArticleDrugmakers seize on biomarkers to test the FDA's rare disease shift
For the first time, the FDA will consider whether to approve a trio of drugs for tiny patient populations based on trials that are using new biological signals as outcomes, rather than a placebo...
View ArticleGH Research reports Phase 2b triumph for short-acting psychedelic drug in...
GH Research has shared compelling data in people with a traditionally challenging form of depression who were dosed with its psychedelic candidate, despite the drug being under a clinical hold in the...
View ArticleThermo Fisher to lay off 300 workers at two viral vector factories
Thermo Fisher Scientific is cutting 300 employees across two viral vector manufacturing facilities in Massachusetts, marking the second round of layoffs at those factories in the past few months. The...
View Article